CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Although rAAV2 vectors have been used for efficient transduction in various cells and tissue types, and are used in clinical trials [33-36], the transduction of primary human CML cells or CD34+ PBPC had been hindered by the low susceptibility of those cells.